Abpro Bio (A195990) 주식 개요앱프로바이오(주)는 국내 및 해외에서 공작기계를 제조 및 판매하는 기업입니다. 자세히 보기A195990 펀더멘털 분석스노우플레이크 점수가치 평가1/6미래 성장0/6과거 실적0/6재무 건전성5/6배당0/6위험 분석지난 5년간 매년 수익이 19.3% 감소했습니다.지난 3개월 동안 주가 변동성이 KR 시장과 비교했을 때 매우 높았습니다.의미 있는 시가총액이 없습니다(₩30B)모든 위험 점검 보기A195990 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩921.0020.4% 저평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-44b64b2016201920222025202620282031Revenue ₩27.3bEarnings ₩2.5bAdvancedSet Fair ValueView all narrativesAbpro Bio Co., Ltd. 경쟁사Global SM TechSymbol: KOSDAQ:A900070Market cap: ₩32.1bBoosterSymbol: KOSDAQ:A008470Market cap: ₩25.6bNEXTURN&ROLLKOREASymbol: KOSDAQ:A089140Market cap: ₩37.9bEssen TechSymbol: KOSDAQ:A043340Market cap: ₩37.6b가격 이력 및 성과Abpro Bio 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩921.0052주 최고가₩4,470.0052주 최저가₩900.00베타-0.271개월 변동-21.35%3개월 변동-16.27%1년 변동-69.90%3년 변동-81.54%5년 변동-92.69%IPO 이후 변동-97.77%최근 뉴스 및 업데이트공시 • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.공시 • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).분석 기사 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).더 많은 업데이트 보기Recent updates공시 • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.공시 • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).분석 기사 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).분석 기사 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).분석 기사 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...분석 기사 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...분석 기사 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).공시 • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea분석 기사 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.분석 기사 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).분석 기사 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).분석 기사 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).공시 • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).분석 기사 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.공시 • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.분석 기사 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.분석 기사 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period.주주 수익률A195990KR MachineryKR 시장7D-3.1%-7.0%-11.9%1Y-69.9%37.4%149.7%전체 주주 수익률 보기수익률 대 산업: A195990은 지난 1년 동안 37.4%의 수익을 기록한 KR Machinery 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A195990은 지난 1년 동안 149.7%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A195990's price volatile compared to industry and market?A195990 volatilityA195990 Average Weekly Movement20.8%Machinery Industry Average Movement9.2%Market Average Movement8.6%10% most volatile stocks in KR Market16.0%10% least volatile stocks in KR Market4.4%안정적인 주가: A195990의 주가는 지난 3개월 동안 KR 시장보다 변동성이 컸습니다.시간에 따른 변동성: A195990의 주간 변동성은 지난 1년간 15%에서 21%로 증가했습니다.회사 소개설립직원 수CEO웹사이트199145Lee Jae-yongwww.abprobio.co.kr앱프로바이오(주)는 국내 및 해외에서 공작 기계를 제조 및 판매하는 회사입니다. 탭핑 센터, 스핀들 머신, 머시닝 및 터닝 센터, 긴 테이블이 있는 머시닝 센터를 제공합니다. 이 회사는 1991년에 설립되었으며 대한민국 대구에 본사를 두고 있습니다.더 보기Abpro Bio Co., Ltd. 기초 지표 요약Abpro Bio의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A195990 기초 통계시가총액₩30.00b순이익 (TTM)-₩43.59b매출 (TTM)₩30.94b1.0x주가매출비율(P/S)-0.7x주가수익비율(P/E)A195990는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A195990 손익계산서 (TTM)매출₩30.94b매출원가₩27.53b총이익₩3.41b기타 비용₩46.99b순이익-₩43.59b최근 보고된 실적Mar 31, 2026다음 실적 발표일해당 없음주당순이익(EPS)-1.34k총이익률11.02%순이익률-140.89%부채/자본 비율25.5%A195990의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/10 06:40종가2026/06/10 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Abpro Bio Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.
공시 • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.
Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
분석 기사 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...
New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).
공시 • Apr 02Abpro Bio Co., Ltd. announced that it has received KRW 3.9999998 billion in fundingOn March 31, 2026, Abpro Bio Co., Ltd. closed the transaction.
공시 • Mar 17+ 2 more updatesAbpro Bio Co., Ltd. announced that it expects to receive KRW 6 billion in fundingAbpro Bio Co., Ltd. anounced a private placement to issue Zero Coupon Series 19 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 and for gross proceeds of KRW 3,000,000,000 and Zero Coupon Series 18 Unregistered Unsecured Private Convertible Bonds due April 30, 2029 for gross proceeds of KRW 3,000,000,000; aggregate gross proceeds of KRW 6,000,000,000 on March 16, 2026. The transaction will include participation from new investors Lee Ho-dong KRW 1,000,000,000, Ha Chang Hyeon KRW 1,000,000,000, Kim Min-seop KRW 500,000,000, Baek Jewoo KRW 250,000,000 and Baek Min-wook KRW 250,000,000. The transaction has been approved by shareholders, expected to close on April 30, 2026, bears zero coupon rate, 3% maturity rate. matures on April 30, 2029, 100% convertible into 2,265,861 shares at a fixed conversion price of KRW 1,324 from April 30, 2027 to March 30, 2029 and restricted to a hold period. Series 18 bonds - Transaction involves participation of Raeun Company Co., Ltd. as an investor. Bond bear 0% interest and yield to maturity rate is 3%. Bond matures on April 10, 2029 and conversion price is KRW 1,324. Transaction is approved by board of directors and is expected to close by April 10, 2026. Bonds are restricted for 1 year from closing.
Board Change • Mar 12No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. CEO & Executive Director Lee Jae-yong was the last director to join the board, commencing their role in 2024. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
New Risk • Feb 20New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₩3.99b (US$2.76m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Earnings have declined by 5.6% per year over the past 5 years. Market cap is less than US$10m (₩3.99b market cap, or US$2.76m). Minor Risk Share price has been volatile over the past 3 months (11% average weekly change).
분석 기사 • Jan 06Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 31%Abpro Bio Co., Ltd. ( KOSDAQ:195990 ) shares have retraced a considerable 31% in the last month, reversing a fair...
New Risk • Nov 29New major risk - Revenue and earnings growthEarnings have declined by 5.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩22b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 5.6% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩86.3b market cap, or US$58.7m).
분석 기사 • Nov 05Abpro Bio Co., Ltd.'s (KOSDAQ:195990) 27% Price Boost Is Out Of Tune With RevenuesAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders are no doubt pleased to see that the share price has bounced 27% in...
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of South Korean stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩20b free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Minor Risk Market cap is less than US$100m (₩69.2b market cap, or US$47.9m).
분석 기사 • Nov 03Would Abpro Bio (KOSDAQ:195990) Be Better Off With Less Debt?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
분석 기사 • Aug 18Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Popularity With Investors Under Threat As Stock Sinks 27%KOSDAQ:A195990 1 Year Share Price vs Fair Value Explore Abpro Bio's Fair Values from the Community and select yours The...
분석 기사 • Jul 25Abpro Bio (KOSDAQ:195990) Is Making Moderate Use Of DebtHoward Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • May 23New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩19b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risk Less than 1 year of cash runway based on free cash flow trend (-₩19b free cash flow). Minor Risk Market cap is less than US$100m (₩85.7b market cap, or US$62.4m).
New Risk • Mar 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩22b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩22b). Market cap is less than US$100m (₩88.0b market cap, or US$60.0m).
공시 • Mar 19Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025Abpro Bio Co., Ltd., Annual General Meeting, Mar 28, 2025, at 09:01 Tokyo Standard Time. Location: conference room, 70, techno sunhwan-ro 1-gil, yuga-eup, dalseong-gun, daegu South Korea
분석 기사 • Mar 12Abpro Bio Co., Ltd.'s (KOSDAQ:195990) Share Price Could Signal Some RiskAbpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 3x may look like a poor investment...
New Risk • Dec 16New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. This is currently the only risk that has been identified for the company.
분석 기사 • Dec 06Abpro Bio Co., Ltd. (KOSDAQ:195990) Shares May Have Slumped 29% But Getting In Cheap Is Still UnlikelyAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders won't be pleased to see that the share price has had a very rough...
New Risk • Nov 22New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩138.1b (US$98.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Market cap is less than US$100m (₩138.1b market cap, or US$98.6m).
분석 기사 • Oct 21We Think Abpro Bio (KOSDAQ:195990) Has A Fair Chunk Of DebtSome say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
New Risk • Aug 28New minor risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow. Free cash flow: -₩9.7b This is considered a minor risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Minor Risks Less than 1 year of cash runway based on current free cash flow (-₩9.7b). Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩126.7b market cap, or US$94.9m).
분석 기사 • Jul 12Getting In Cheap On Abpro Bio Co., Ltd. (KOSDAQ:195990) Is UnlikelyWhen close to half the companies in the Machinery industry in Korea have price-to-sales ratios (or "P/S") below 1x, you...
New Risk • Jun 21New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩136.1b (US$97.8m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (2.7% increase in shares outstanding). Market cap is less than US$100m (₩136.1b market cap, or US$97.8m).
공시 • Jun 18Abpro Bio Co., Ltd. announced that it has received KRW 6 billion in funding from Sangsangin Investment & Securities Co.,Ltd., Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On June 17, 2024, Abpro Bio Co., Ltd. closed the transaction.
New Risk • Apr 15New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩137.8b (US$99.6m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Shareholders have been diluted in the past year (4.0% increase in shares outstanding). Market cap is less than US$100m (₩137.8b market cap, or US$99.6m).
분석 기사 • Mar 14Revenues Not Telling The Story For Abpro Bio Co., Ltd. (KOSDAQ:195990)Abpro Bio Co., Ltd.'s ( KOSDAQ:195990 ) price-to-sales (or "P/S") ratio of 6.4x may look like a poor investment...
New Risk • Nov 30New major risk - Revenue and earnings growthEarnings have declined by 1.7% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 1.7% per year over the past 5 years. Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Oct 18New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 3.9% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risk Shareholders have been diluted in the past year (3.9% increase in shares outstanding).
New Risk • Jun 30New minor risk - Market cap sizeThe company's market capitalization is less than US$100m. Market cap: ₩130.6b (US$98.9m) This is considered a minor risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Earnings have declined by 2.7% per year over the past 5 years. Minor Risks Shareholders have been diluted in the past year (2.1% increase in shares outstanding). Market cap is less than US$100m (₩130.6b market cap, or US$98.9m).
Board Change • Nov 16No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Sep 28Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion.Abpro Bio Co., Ltd. (KOSDAQ:A195990) agreed to acquire 30.911846% stake in Zinitix Co., Ltd. (KOSDAQ:A303030) from Seoul Electronic Communication Co., Ltd., Wonwoo Kim, Soo-ah Kim for KRW 37 billion on September 26, 2022. As per the terms, the offer per share is KRW 3348 per share. Total number of shares acquired are 11,049,646. Transaction is expected to be closed on November 8, 2022.
Board Change • Apr 27No independent directorsFollowing the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 4 non-independent directors. Director Bob Langer was the last director to join the board, commencing their role in 2020. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model.
Reported Earnings • Apr 03Full year 2021 earnings released: ₩36.91 loss per share (vs ₩198 loss in FY 2020)Full year 2021 results: ₩36.91 loss per share (up from ₩198 loss in FY 2020). Revenue: ₩32.9b (down 8.1% from FY 2020). Net loss: ₩9.26b (loss narrowed 78% from FY 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year whereas the company’s share price has increased by 4% per year.
공시 • Jun 17Abpro Bio Co., Ltd. announced that it expects to receive KRW 15 billion in funding from Meritz Securities Co., Ltd., Investment ArmAbpro Bio Co., Ltd. (KOSDAQ:A195990) announced a private placement of series 16 unregistered coupon non-guaranteed private convertible bonds for the gross proceeds of KRW 15,000,000,000 on June 16, 2021. The transaction will include participation from Meritz Securities Co., Ltd., Investment Arm. The bonds carry coupon rate of 2% and interest rate to maturity 2%. The bonds have maturity date of June 18, 2024. The bonds can be 100% converted into 11,244,377 common shares of the company at a fixed conversion price of KRW 1,334 per share, representing the stake of 4.47% in the company. The conversion period start date is June 19, 2022 and end date is June 12, 2024. The subscription date is June 16, 2021. The payment date is June 18, 2021. The transaction has been approved by the company’s board of directors. The bonds carry a hold period of one year.
분석 기사 • Apr 05Is Abpro Bio (KOSDAQ:195990) Using Debt In A Risky Way?David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Is New 90 Day High Low • Feb 17New 90-day low: ₩1,055The company is down 58% from its price of ₩2,515 on 19 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Machinery industry, which is up 11% over the same period.
분석 기사 • Feb 02Abpro Bio (KOSDAQ:195990) Shareholders Booked A 92% Gain In The Last YearAbpro Bio Co., Ltd. ( KOSDAQ:195990 ) shareholders might be concerned after seeing the share price drop 27% in the last...
Is New 90 Day High Low • Nov 17New 90-day high: ₩1,490The company is up 110% from its price of ₩710 on 19 August 2020. The South Korean market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is up 13% over the same period.
Is New 90 Day High Low • Nov 02New 90-day high: ₩834The company is up 5.0% from its price of ₩797 on 04 August 2020. The South Korean market is flat over the last 90 days, indicating the company outperformed over that time. It also outperformed the Machinery industry, which is down 3.0% over the same period.
